Capricor Therapeutics (CAPR) Common Equity (2016 - 2025)
Historic Common Equity for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $83.9 million.
- Capricor Therapeutics' Common Equity rose 2285.55% to $83.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.9 million, marking a year-over-year increase of 2285.55%. This contributed to the annual value of $145.5 million for FY2024, which is 54359.69% up from last year.
- Per Capricor Therapeutics' latest filing, its Common Equity stood at $83.9 million for Q3 2025, which was up 2285.55% from $105.0 million recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' Common Equity ranged from a high of $145.5 million in Q4 2024 and a low of -$1.8 million during Q3 2023
- For the 5-year period, Capricor Therapeutics' Common Equity averaged around $42.0 million, with its median value being $24.6 million (2022).
- Per our database at Business Quant, Capricor Therapeutics' Common Equity crashed by 11158.82% in 2023 and then surged by 391868.54% in 2024.
- Over the past 5 years, Capricor Therapeutics' Common Equity (Quarter) stood at $31.4 million in 2021, then tumbled by 62.43% to $11.8 million in 2022, then surged by 91.76% to $22.6 million in 2023, then skyrocketed by 543.6% to $145.5 million in 2024, then tumbled by 42.34% to $83.9 million in 2025.
- Its Common Equity stands at $83.9 million for Q3 2025, versus $105.0 million for Q2 2025 and $127.6 million for Q1 2025.